Seminars in liver disease最新文献_第10页

GAS6/TAM Axis as Therapeutic Target in Liver Diseases. 作为肝病治疗靶点的 GAS6/TAM 轴。

IF 3.7 3区医学

Seminars in liver disease Pub Date : 2024-02-01 Epub Date: 2024-02-23 DOI: 10.1055/a-2275-0408

Anna Tutusaus, Albert Morales, Pablo García de Frutos, Montserrat Marí

{"title":"GAS6/TAM Axis as Therapeutic Target in Liver Diseases.","authors":"Anna Tutusaus, Albert Morales, Pablo García de Frutos, Montserrat Marí","doi":"10.1055/a-2275-0408","DOIUrl":"10.1055/a-2275-0408","url":null,"abstract":"TAM (TYRO3, AXL, and MERTK) protein tyrosine kinase membrane receptors and their vitamin K-dependent ligands GAS6 and protein S (PROS) are well-known players in tumor biology and autoimmune diseases. In contrast, TAM regulation of fibrogenesis and the inflammation mechanisms underlying metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, and, ultimately, liver cancer has recently been revealed. GAS6 and PROS binding to phosphatidylserine exposed in outer membranes of apoptotic cells links TAMs, particularly MERTK, with hepatocellular damage. In addition, AXL and MERTK regulate the development of liver fibrosis and inflammation in chronic liver diseases. Acute hepatic injury is also mediated by the TAM system, as recent data regarding acetaminophen toxicity and acute-on-chronic liver failure have uncovered. Soluble TAM-related proteins, mainly released from activated macrophages and hepatic stellate cells after hepatic deterioration, are proposed as early serum markers for disease progression. In conclusion, the TAM system is becoming an interesting pharmacological target in liver pathology and a focus of future biomedical research in this field.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"99-114"},"PeriodicalIF":3.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11027478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139940678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune Checkpoint Inhibitor-Induced Liver Injury 免疫检查点抑制剂诱发的肝损伤

IF 4.2 3区医学

Seminars in liver disease Pub Date : 2023-12-15 DOI: 10.1055/s-0043-1776761

Cathrin L.C. Gudd, Roosey Sheth, Mark R. Thursz, Evangelos Triantafyllou, Lucia A. Possamai

引用次数: 0

Novel Therapeutic Approaches in Treatment of Acute-on-Chronic Liver Failure 治疗急性慢性肝衰竭的新疗法

IF 4.2 3区医学

Seminars in liver disease Pub Date : 2023-12-15 DOI: 10.1055/s-0043-1776773

MohammadMahdi Saeidinejad, Ahmed Elshabrawi, Supachaya Sriphoosanaphan, Fausto Andreola, Gautam Mehta, Banwari Agarwal, Rajiv Jalan

引用次数: 0

The Ploidy State as a Determinant of Hepatocyte Proliferation. 倍性状态是肝细胞增殖的决定因素。

IF 4.2 3区医学

Seminars in liver disease Pub Date : 2023-11-01 Epub Date: 2023-11-15 DOI: 10.1055/a-2211-2144

Sierra R Wilson, Andrew W Duncan

引用次数: 0

Hedgehog Signaling: Implications in Liver Pathophysiology. Hedgehog信号传导：肝脏病理生理学的意义。

IF 4.2 3区医学

Seminars in liver disease Pub Date : 2023-11-01 Epub Date: 2023-10-06 DOI: 10.1055/a-2187-3382

Rajesh Kumar Dutta, JiHye Jun, Kuo Du, Anna Mae Diehl

{"title":"Hedgehog Signaling: Implications in Liver Pathophysiology.","authors":"Rajesh Kumar Dutta, JiHye Jun, Kuo Du, Anna Mae Diehl","doi":"10.1055/a-2187-3382","DOIUrl":"10.1055/a-2187-3382","url":null,"abstract":"The purpose of this review is to summarize current knowledge about the role of the Hedgehog signaling pathway in liver homeostasis and disease. Hedgehog is a morphogenic signaling pathway that is active in development. In most healthy tissues, pathway activity is restricted to stem and/or stromal cell compartments, where it enables stem cell self-renewal and tissue homeostasis. Aberrant over-activation of Hedgehog signaling occurs in many cancers, including hepatocellular and cholangio-carcinoma. The pathway is also activated transiently in stromal cells of injured tissues and orchestrates normal wound healing responses, including inflammation, vascular remodeling, and fibrogenesis. In liver, sustained Hedgehog signaling in stromal cells plays a major role in the pathogenesis of cirrhosis. Hedgehog signaling was thought to be silenced in healthy hepatocytes. However, recent studies show that targeted disruption of the pathway in hepatocytes dysregulates lipid, cholesterol, and bile acid metabolism, and promotes hepatic lipotoxicity, insulin resistance, and senescence. Hepatocytes that lack Hedgehog activity also produce a secretome that activates Hedgehog signaling in cholangiocytes and neighboring stromal cells to induce inflammatory and fibrogenic wound healing responses that drive progressive fibrosis. In conclusion, Hedgehog signaling must be precisely controlled in adult liver cells to maintain liver health.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"418-428"},"PeriodicalIF":4.2,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41170492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Hepatic Porphyrias: Revealing the Complexities of a Rare Disease. 肝卟啉症:揭示一种罕见疾病的复杂性。

IF 4.3 3区医学

Seminars in liver disease Pub Date : 2023-11-01 Epub Date: 2023-11-16 DOI: 10.1055/s-0043-1776760

Oluwashanu Balogun, Kari Nejak-Bowen

引用次数: 0

Biliary Tract Cancer: Molecular Biology of Precursor Lesions. 癌症胆道：前驱病变的分子生物学。

IF 4.2 3区医学

Seminars in liver disease Pub Date : 2023-11-01 Epub Date: 2023-11-09 DOI: 10.1055/a-2207-9834

Fátima Manzano-Núñez, Lara Prates Tiago Aguilar, Christine Sempoux, Frédéric P Lemaigre

引用次数: 0

Mechanisms of Lipid Droplet Accumulation in Steatotic Liver Diseases. 脂滴在脂肪性肝病中积聚的机制。

IF 4.2 3区医学

Seminars in liver disease Pub Date : 2023-11-01 Epub Date: 2023-10-05 DOI: 10.1055/a-2186-3557

Joseph L Dempsey, George N Ioannou, Rotonya M Carr

{"title":"Mechanisms of Lipid Droplet Accumulation in Steatotic Liver Diseases.","authors":"Joseph L Dempsey, George N Ioannou, Rotonya M Carr","doi":"10.1055/a-2186-3557","DOIUrl":"10.1055/a-2186-3557","url":null,"abstract":"The steatotic diseases of metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), and chronic hepatitis C (HCV) account for the majority of liver disease prevalence, morbidity, and mortality worldwide. While these diseases have distinct pathogenic and clinical features, dysregulated lipid droplet (LD) organelle biology represents a convergence of pathogenesis in all three. With increasing understanding of hepatocyte LD biology, we now understand the roles of LD proteins involved in these diseases but also how genetics modulate LD biology to either exacerbate or protect against the phenotypes associated with steatotic liver diseases. Here, we review the history of the LD organelle and its biogenesis and catabolism. We also review how this organelle is critical not only for the steatotic phenotype of liver diseases but also for their advanced phenotypes. Finally, we summarize the latest attempts and challenges of leveraging LD biology for therapeutic gain in steatotic diseases. In conclusion, the study of dysregulated LD biology may lead to novel therapeutics for the prevention of disease progression in the highly prevalent steatotic liver diseases of MASLD, ALD, and HCV.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"367-382"},"PeriodicalIF":4.2,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41150633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unraveling the Complexities of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. 揭示肝细胞癌中免疫检查点抑制剂的复杂性。

IF 4.2 3区医学

Seminars in liver disease Pub Date : 2023-11-01 Epub Date: 2023-11-06 DOI: 10.1055/s-0043-1776127

Xinpu Han, Qianhui Sun, Manman Xu, Guanghui Zhu, Ruike Gao, Baoyi Ni, Jie Li

{"title":"Unraveling the Complexities of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.","authors":"Xinpu Han, Qianhui Sun, Manman Xu, Guanghui Zhu, Ruike Gao, Baoyi Ni, Jie Li","doi":"10.1055/s-0043-1776127","DOIUrl":"10.1055/s-0043-1776127","url":null,"abstract":"Immune checkpoint inhibitors (ICIs) have emerged as effective therapeutics for multiple cancers. Nevertheless, as immunotherapeutic approaches are being extensively utilized, substantial hurdles have arisen for clinicians. These include countering ICIs resistance and ensuring precise efficacy assessments of these drugs, especially in the context of hepatocellular carcinoma (HCC). This review attempts to offer a holistic overview of the latest insights into the ICIs resistance mechanisms in HCC, the molecular underpinnings, and immune response. The intent is to inspire the development of efficacious combination strategies. This review also examines the unconventional response patterns, namely pseudoprogression (PsP) and hyperprogression (HPD). The prompt and rigorous evaluation of these treatment efficacies has emerged as a crucial imperative. Multiple clinical, radiological, and biomarker tests have been advanced to meticulously assess tumor response. Despite progress, precise mechanisms of action and predictive biomarkers remain elusive. This necessitates further investigation through prospective cohort studies in the impending future.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"383-401"},"PeriodicalIF":4.2,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71485746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gut Microbiome-Centered Therapies for Alcohol-Associated Liver Disease. 以肠道微生物组为中心的酒精相关性肝病治疗。

IF 4.2 3区医学

Seminars in liver disease Pub Date : 2023-08-01 DOI: 10.1055/a-2145-7331

Tannaz Ranjbarian, Bernd Schnabl

{"title":"Gut Microbiome-Centered Therapies for Alcohol-Associated Liver Disease.","authors":"Tannaz Ranjbarian, Bernd Schnabl","doi":"10.1055/a-2145-7331","DOIUrl":"10.1055/a-2145-7331","url":null,"abstract":"Globally, liver disease caused by alcohol is becoming more prevalent each year. Misuse of alcohol causes a spectrum of liver diseases, such as liver steatosis, steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. The cornerstone of treatment is abstinence from alcohol. In spite of this, available treatment for alcohol-associated liver disease (ALD) shows limited effectiveness currently. There are numerous ways in which alcohol disrupts the gut-liver axis, including dysbiosis of the gut microbiome, disruption of mucus and epithelial cell barriers, impaired production of antimicrobial molecules, and dysfunction of the immune system, causing translocation of viable microbes and microbial products to the liver and systemic circulation. Microbial exposure results in not only inflammation and progression of liver disease but also infections in late-stage ALD. This led scientists to focus their therapeutic strategies and targets for ALD on the gut microbiome. Throughout this review, we address the role of gut microbiome-centered therapeutic approaches for ALD focusing predominantly on randomized controlled trials. We will summarize the latest clinical trials using probiotics, antibiotics, and fecal microbial transplants in modulating the gut-liver axis and for improvement of ALD.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"311-322"},"PeriodicalIF":4.2,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10172577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0